President Trump seeks to honor his campaign promise of lower U.S. medical costs by forcing higher big-pharma prices in foreign countries.

Charlene Vos

2018-05-07 07:32:00 Mon ET

President Trump seeks to honor his campaign promise of lower U.S. medical costs by forcing higher big-pharma prices in foreign countries such as Canada, Britain, France, Germany, Japan, and South Korea. As of early-2018, the typical American spends more than $1,100 on prescription drugs per year.

It is true that many Americans take pills on a regular basis, but what sets the U.S. apart from most other OECD countries relates to high drug prices. President Trump now attempts to induce large pharmaceutical companies such as Merck, Johnson & Johnson, Pfizer, Amgen, and GSK etc to increase their medicine prices abroad. This strategic move would create economic incentives for these companies to cut drug prices in America. In light of the high health insurance and medical costs in America, the Trump administration either has to foster competition among biotech firms and pharmaceutical companies, or the Trump administration needs to induce them to voluntarily reduce medicine prices.

President Trump sometimes retorts with the deliberate hyperbole that drugmakers can **get away with murder** in what they charge the government for medication. As the American population enjoys longer human longevity with better medical technology, lower medicine prices seem to have become a necessary evil for big pharma.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Louis Kaplow strives to find a delicate balance between efficiency gains and redistributive taxes in the social welfare function.

Chanel Holden

2023-07-07 10:29:00 Friday ET

Louis Kaplow strives to find a delicate balance between efficiency gains and redistributive taxes in the social welfare function.

Louis Kaplow strives to find a delicate balance between efficiency gains and redistributive taxes in the social welfare function. Louis Kaplow (2010)

+See More

Modern themes and insights in behavioral finance (Part 1)

Laura Hermes

2022-02-05 09:26:00 Saturday ET

Modern themes and insights in behavioral finance (Part 1)

Modern themes and insights in behavioral finance   Shiller, R.J. (2003). From efficient markets theory to behavioral finance. Journal of Economi

+See More

Tony Robbins suggests that one has to be able to make money during sleep hours in order to reach financial freedom.

Laura Hermes

2019-04-27 16:41:00 Saturday ET

Tony Robbins suggests that one has to be able to make money during sleep hours in order to reach financial freedom.

Tony Robbins suggests that one has to be able to make money during sleep hours in order to reach financial freedom. Most of our jobs and life experiences tr

+See More

President Donald Trump blames China for the long prevalent U.S. trade deficits and several other social and economic deficiencies.

Apple Boston

2025-01-22 08:35:08 Wednesday ET

President Donald Trump blames China for the long prevalent U.S. trade deficits and several other social and economic deficiencies.

President Donald Trump blames China for the long prevalent U.S. trade deficits and several other social and economic deficiencies. In recent years, Pres

+See More

Goldman, JPMorgan, Bank of America, Credit Suisse, Morgan Stanley, and UBS face an antitrust lawsuit.

Daphne Basel

2018-09-30 14:34:00 Sunday ET

Goldman, JPMorgan, Bank of America, Credit Suisse, Morgan Stanley, and UBS face an antitrust lawsuit.

Goldman, JPMorgan, Bank of America, Credit Suisse, Morgan Stanley, and UBS face an antitrust lawsuit. In this lawsuit, a U.S. judge alleges the illegal cons

+See More

France and Germany are the biggest beneficiaries of Sino-U.S. trade escalation.

Chanel Holden

2019-07-11 10:48:00 Thursday ET

France and Germany are the biggest beneficiaries of Sino-U.S. trade escalation.

France and Germany are the biggest beneficiaries of Sino-U.S. trade escalation, whereas, Japan, South Korea, and Taiwan suffer from the current trade stando

+See More